secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-10-01T13:00:29+00:00
Accession:  0001645113-26-000071
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Novocure's Optune Pax wins Japan MHLW approval for unresectable locally advanced pancreatic cancer
--------------------------------------------------------------------------------

- Japan's MHLW approved Optune Pax for adults with unresectable locally advanced pancreatic cancer, given with gemcitabine and nab-paclitaxel.
- Approval based on Phase 3 PANOVA-3, which met its primary endpoint with statistically significant improvement in median overall survival vs chemo alone; pain progression delayed.
- No new safety signals; device-related skin adverse events under arrays in 76.3% of Optune Pax patients, mostly Grade 1-2, with 21 (7.7%) Grade 3 or higher.
- Optune Pax was FDA-approved in February 2026 and received CE Mark in June 2026; Japan sees ~46,000 pancreatic cancer diagnoses yearly with 12% five-year relative survival.
- Novocure cited Makoto Ueno of Kanagawa Cancer Center and Hidehito Kotani, SVP Head of Asia Pacific, in the October 1, 2026 announcement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000071/0001645113-26-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000071/nvcr-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer